VistaGen Therapeutics (VTGN) Competitors

$0.60 -0.03 (-4.70%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$0.62 +0.02 (+3.44%)

As of 04:22 AM Eastern

VTGN vs. COYA, LONA, FRMM, ATYR, and UPXI

Should you buy VistaGen Therapeutics stock or one of its competitors? MarketBeat compares VistaGen Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with VistaGen Therapeutics include Coya Therapeutics (COYA), Athira Pharma (LONA), Forum Markets (FRMM), aTyr Pharma (ATYR), and Upexi (UPXI). These companies are all part of the "pharmaceutical products" industry.

How does VistaGen Therapeutics compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

VistaGen Therapeutics has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. Coya Therapeutics' return on equity of -55.86% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-266.10%	-55.86%	-48.86%
VistaGen Therapeutics	N/A	-109.72%	-89.62%

In the previous week, Coya Therapeutics had 10 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 12 mentions for Coya Therapeutics and 2 mentions for VistaGen Therapeutics. VistaGen Therapeutics' average media sentiment score of 0.94 beat Coya Therapeutics' score of 0.60 indicating that VistaGen Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coya Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
VistaGen Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Coya Therapeutics has higher revenue and earnings than VistaGen Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	14.52	-$21.23M	-$1.15	N/A
VistaGen Therapeutics	$490K	48.15	-$51.42M	-$1.89	N/A

Coya Therapeutics currently has a consensus price target of $16.00, indicating a potential upside of 225.20%. VistaGen Therapeutics has a consensus price target of $0.95, indicating a potential upside of 59.53%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Coya Therapeutics is more favorable than VistaGen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Coya Therapeutics has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are held by institutional investors. 12.0% of Coya Therapeutics shares are held by insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Coya Therapeutics beats VistaGen Therapeutics on 11 of the 16 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Athira Pharma?

VistaGen Therapeutics (NASDAQ:VTGN) and Athira Pharma (NASDAQ:LONA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

VistaGen Therapeutics has higher revenue and earnings than Athira Pharma. Athira Pharma is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$490K	48.15	-$51.42M	-$1.89	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A

VistaGen Therapeutics' return on equity of -109.72% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	N/A	-109.72%	-89.62%
Athira Pharma	N/A	-381.01%	-225.74%

In the previous week, VistaGen Therapeutics had 1 more articles in the media than Athira Pharma. MarketBeat recorded 2 mentions for VistaGen Therapeutics and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.94 beat VistaGen Therapeutics' score of 0.94 indicating that Athira Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VistaGen Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Athira Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

VistaGen Therapeutics currently has a consensus price target of $0.95, indicating a potential upside of 59.53%. Athira Pharma has a consensus price target of $10.00, indicating a potential downside of 1.28%. Given VistaGen Therapeutics' higher probable upside, research analysts clearly believe VistaGen Therapeutics is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

VistaGen Therapeutics has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Athira Pharma has a beta of 1.98, meaning that its share price is 98% more volatile than the broader market.

78.4% of VistaGen Therapeutics shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 2.9% of VistaGen Therapeutics shares are held by company insiders. Comparatively, 25.7% of Athira Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

VistaGen Therapeutics beats Athira Pharma on 9 of the 14 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Forum Markets?

VistaGen Therapeutics (NASDAQ:VTGN) and Forum Markets (NASDAQ:FRMM) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

VistaGen Therapeutics has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Forum Markets has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market.

VistaGen Therapeutics currently has a consensus target price of $0.95, indicating a potential upside of 59.53%. Forum Markets has a consensus target price of $10.00, indicating a potential upside of 168.10%. Given Forum Markets' stronger consensus rating and higher probable upside, analysts plainly believe Forum Markets is more favorable than VistaGen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Forum Markets	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

78.4% of VistaGen Therapeutics shares are held by institutional investors. Comparatively, 4.1% of Forum Markets shares are held by institutional investors. 2.9% of VistaGen Therapeutics shares are held by insiders. Comparatively, 15.1% of Forum Markets shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

VistaGen Therapeutics has higher earnings, but lower revenue than Forum Markets. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$490K	48.15	-$51.42M	-$1.89	N/A
Forum Markets	$6.55M	11.57	-$450.52M	-$36.07	N/A

In the previous week, Forum Markets had 4 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 6 mentions for Forum Markets and 2 mentions for VistaGen Therapeutics. VistaGen Therapeutics' average media sentiment score of 0.94 beat Forum Markets' score of 0.61 indicating that VistaGen Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VistaGen Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Forum Markets	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

VistaGen Therapeutics' return on equity of -109.72% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	N/A	-109.72%	-89.62%
Forum Markets	N/A	-225.87%	-117.50%

Summary

Forum Markets beats VistaGen Therapeutics on 9 of the 16 factors compared between the two stocks.

How does VistaGen Therapeutics compare to aTyr Pharma?

VistaGen Therapeutics (NASDAQ:VTGN) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

VistaGen Therapeutics has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$490K	48.15	-$51.42M	-$1.89	N/A
aTyr Pharma	$190K	268.09	-$74.12M	-$0.73	N/A

VistaGen Therapeutics has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

78.4% of VistaGen Therapeutics shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 2.9% of VistaGen Therapeutics shares are owned by insiders. Comparatively, 5.8% of aTyr Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

VistaGen Therapeutics presently has a consensus price target of $0.95, indicating a potential upside of 59.53%. aTyr Pharma has a consensus price target of $25.67, indicating a potential upside of 4,840.65%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts plainly believe aTyr Pharma is more favorable than VistaGen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, aTyr Pharma had 6 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 8 mentions for aTyr Pharma and 2 mentions for VistaGen Therapeutics. VistaGen Therapeutics' average media sentiment score of 0.94 beat aTyr Pharma's score of 0.44 indicating that VistaGen Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VistaGen Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
aTyr Pharma	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

aTyr Pharma's return on equity of -94.64% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	N/A	-109.72%	-89.62%
aTyr Pharma	N/A	-94.64%	-69.75%

Summary

aTyr Pharma beats VistaGen Therapeutics on 10 of the 15 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Upexi?

Upexi (NASDAQ:UPXI) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

5.7% of Upexi shares are held by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are held by institutional investors. 9.0% of Upexi shares are held by company insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Upexi has higher revenue and earnings than VistaGen Therapeutics. Upexi is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upexi	$26.14M	3.55	-$13.68M	-$3.23	N/A
VistaGen Therapeutics	$490K	48.15	-$51.42M	-$1.89	N/A

Upexi presently has a consensus target price of $8.33, indicating a potential upside of 531.31%. VistaGen Therapeutics has a consensus target price of $0.95, indicating a potential upside of 59.53%. Given Upexi's stronger consensus rating and higher possible upside, equities analysts clearly believe Upexi is more favorable than VistaGen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Upexi has a beta of -0.32, suggesting that its stock price is 132% less volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

In the previous week, Upexi had 6 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 8 mentions for Upexi and 2 mentions for VistaGen Therapeutics. VistaGen Therapeutics' average media sentiment score of 0.94 beat Upexi's score of -0.22 indicating that VistaGen Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Upexi	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
VistaGen Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

VistaGen Therapeutics has a net margin of 0.00% compared to Upexi's net margin of -874.00%. Upexi's return on equity of -66.70% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upexi	-874.00%	-66.70%	-19.56%
VistaGen Therapeutics	N/A	-109.72%	-89.62%

Summary

Upexi beats VistaGen Therapeutics on 10 of the 17 factors compared between the two stocks.

Get VistaGen Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VTGN vs. The Competition

Export

Metric	VistaGen Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$24.76M	$3.31B	$6.25B	$12.29B
Dividend Yield	N/A	2.34%	2.80%	5.30%
P/E Ratio	-0.32	18.13	20.86	25.23
Price / Sales	48.15	275.82	552.57	80.03
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	0.24	6.57	9.67	6.63
Net Income	-$51.42M	$24.35M	$3.56B	$335.59M
7 Day Performance	-4.20%	-2.53%	-1.67%	-1.20%
1 Month Performance	-5.13%	-3.55%	-2.63%	-1.16%
1 Year Performance	-76.65%	53.51%	30.05%	28.10%

VistaGen Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VTGN VistaGen Therapeutics	2.5609 of 5 stars	$0.60 -4.7%	$0.95 +59.5%	-75.8%	$24.76M	$490K	N/A	40
COYA Coya Therapeutics	2.7743 of 5 stars	$4.18 +1.7%	$16.00 +282.8%	-17.0%	$96.41M	$7.95M	N/A	6	News Coverage Earnings Report Analyst Downgrade
LONA Athira Pharma	1.7487 of 5 stars	$10.01 -0.3%	$10.00 -0.1%	N/A	$94.31M	N/A	N/A	40	Analyst Upgrade Gap Down
FRMM Forum Markets	2.4997 of 5 stars	$4.49 -2.6%	$8.00 +78.2%	N/A	$93.64M	$6.55M	N/A	7	Positive News Earnings Report Analyst Downgrade Gap Up
ATYR aTyr Pharma	2.0584 of 5 stars	$0.95 +0.4%	$25.67 +2,601.2%	-84.1%	$92.79M	$190K	N/A	53	Earnings Report Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VTGN) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

VistaGen Therapeutics (VTGN) Competitors

VTGN vs. COYA, LONA, FRMM, ATYR, and UPXI

How does VistaGen Therapeutics compare to Coya Therapeutics?

Summary

How does VistaGen Therapeutics compare to Athira Pharma?

Summary

How does VistaGen Therapeutics compare to Forum Markets?

Summary

How does VistaGen Therapeutics compare to aTyr Pharma?

Summary

How does VistaGen Therapeutics compare to Upexi?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTGN vs. The Competition

VistaGen Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

VistaGen Therapeutics (VTGN) Competitors

VTGN vs. COYA, LONA, FRMM, ATYR, and UPXI

How does VistaGen Therapeutics compare to Coya Therapeutics?

Is COYA or VTGN more profitable?

Does the media prefer COYA or VTGN?

Which has stronger valuation and earnings, COYA or VTGN?

Do analysts rate COYA or VTGN?

Which has more volatility & risk, COYA or VTGN?

Do insiders & institutionals hold more shares of COYA or VTGN?

Summary

How does VistaGen Therapeutics compare to Athira Pharma?

Which has stronger earnings and valuation, VTGN or LONA?

Is VTGN or LONA more profitable?

Does the media refer more to VTGN or LONA?

Do analysts rate VTGN or LONA?

Which has more volatility and risk, VTGN or LONA?

Do institutionals & insiders believe in VTGN or LONA?

Summary

How does VistaGen Therapeutics compare to Forum Markets?

Which has more risk and volatility, VTGN or FRMM?

Do analysts prefer VTGN or FRMM?

Do institutionals & insiders believe in VTGN or FRMM?

Which has higher valuation and earnings, VTGN or FRMM?

Does the media refer more to VTGN or FRMM?

Is VTGN or FRMM more profitable?

Summary

How does VistaGen Therapeutics compare to aTyr Pharma?

Which has better valuation and earnings, VTGN or ATYR?

Which has more volatility and risk, VTGN or ATYR?

Do insiders and institutionals hold more shares of VTGN or ATYR?

Do analysts rate VTGN or ATYR?

Does the media refer more to VTGN or ATYR?

Is VTGN or ATYR more profitable?

Summary

How does VistaGen Therapeutics compare to Upexi?

Do institutionals and insiders believe in UPXI or VTGN?

Which has better earnings and valuation, UPXI or VTGN?

Do analysts rate UPXI or VTGN?

Which has more risk and volatility, UPXI or VTGN?

Does the media favor UPXI or VTGN?

Is UPXI or VTGN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTGN vs. The Competition

VistaGen Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools